Eli Lilly (LLY) Announces 11th Consecutive Dividend Hike Amid Strong Zepbound Sales
Pharmaceutical heavyweight Eli Lilly has raised its quarterly dividend for the eleventh straight year, declaring a $1.50 per share payout for Q3—a marginal increase from $1.49. The MOVE reflects confidence fueled by blockbuster demand for its weight-loss drug Zepbound.
Dividend growth remains robust at a 15% compound annual rate since 2014, though the 0.77% yield trails the S&P 500 average. Analysts attribute the modest payout ratio of 43.74% to aggressive reinvestment in pipeline development rather than shareholder returns.